健之佳(605266.SH)擬出資1.5億元設立子公司購買廠房並建設物流中心
格隆匯8月5日丨健之佳(605266.SH)公吿,2021年8月5日,公司董事會審議通過公司擬以自有資金或募集資金出資1.5億元設立全資子公司廣西健之佳勤康醫藥有限公司(暫定名,簡稱“廣西勤康”),購買廠房並建設物流中心的議案。
該新設立的全資子公司廣西勤康將作為廣西自治區的醫藥批發業務主體,組織架構與其他省級(直轄市)區域保持一致。
物流中心建設項目投入金額:廠房購置及相關税費預計6,934.66萬元;支付第三方平台交易服務費預計15萬元,土建改造裝修預計投入850萬元,設施設備的購買和安裝預計1,173.80萬元,合計8,973.46萬元。
本次擬購買廠房並建設物流中心項目,符合國家政策以及公司的發展規劃,有利於公司進一步拓展門店的建設規劃實施,有助於公司在廣西地區的中長期戰略發展,對公司未來發展具有積極意義和推動作用。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.